Eleven Biotherapeutics Inc. (EBIO) Major Shareholder Ventures Fund Iv L.P Flagship Sells 322,723 Shares
Eleven Biotherapeutics Inc. (NASDAQ:EBIO) major shareholder Ventures Fund Iv L.P Flagship sold 322,723 shares of Eleven Biotherapeutics stock in a transaction dated Wednesday, September 21st. The stock was sold at an average price of $3.75, for a total value of $1,210,211.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Ventures Fund Iv L.P Flagship also recently made the following trade(s):
- On Tuesday, September 20th, Ventures Fund Iv L.P Flagship sold 53,917 shares of Eleven Biotherapeutics stock. The stock was sold at an average price of $3.39, for a total value of $182,778.63.
- On Monday, September 19th, Ventures Fund Iv L.P Flagship sold 9,700 shares of Eleven Biotherapeutics stock. The stock was sold at an average price of $3.31, for a total value of $32,107.00.
Shares of Eleven Biotherapeutics Inc. (NASDAQ:EBIO) traded up 3.86% during midday trading on Wednesday, reaching $3.50. The company had a trading volume of 6,214,655 shares. The stock’s market capitalization is $53.88 million. Eleven Biotherapeutics Inc. has a 1-year low of $0.25 and a 1-year high of $5.97. The company’s 50-day moving average is $4.45 and its 200-day moving average is $2.19.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/eleven-biotherapeutics-inc-ebio-major-shareholder-ventures-fund-iv-l-p-flagship-sells-322723-shares.html
Eleven Biotherapeutics (NASDAQ:EBIO) last released its quarterly earnings results on Friday, August 12th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter. Eleven Biotherapeutics had a negative net margin of 2,995.34% and a negative return on equity of 207.40%. On average, equities research analysts forecast that Eleven Biotherapeutics Inc. will post ($1.75) EPS for the current year.
A number of institutional investors have recently added to or reduced their stakes in EBIO. Sabby Management LLC boosted its position in Eleven Biotherapeutics by 525.6% in the first quarter. Sabby Management LLC now owns 1,213,984 shares of the biopharmaceutical company’s stock valued at $387,000 after buying an additional 1,019,943 shares in the last quarter. Flagship Ventures Fund 2007 L.P. purchased a new position in Eleven Biotherapeutics during the first quarter valued at $610,000. Flagship Ventures Fund IV L.P. purchased a new position in Eleven Biotherapeutics during the first quarter valued at $469,000. Bank of New York Mellon Corp boosted its position in Eleven Biotherapeutics by 13.2% in the second quarter. Bank of New York Mellon Corp now owns 67,483 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 7,846 shares in the last quarter. Finally, Flagship Ventures Fund IV General Partner LLC purchased a new position in Eleven Biotherapeutics during the second quarter valued at $2,464,000. Institutional investors and hedge funds own 24.81% of the company’s stock.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.
Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.